Comparative Effectiveness of Dynamic Treatment Regimes: An Application of the Parametric G-Formula

Statistics in Biosciences

Volumn 3, Issue 1, 2011, Pages 119-143

  Young, Jessica G ^a   Cain, Lauren E ^a   Robins, James M ^a   O'Reilly, Eilis J ^a   Hernán, Miguel A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Causal inference; HIV; Parametric g formula; Survival analysis

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVERSE PROBABILITY; MONTE CARLO METHOD; MORTALITY; PARAMETRIC G FORMULA; PARAMETRIC TEST; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE; VIRUS LOAD;

EID: 80053051431     PISSN: 18671764     EISSN: 18671772     Source Type: Journal    
DOI: 10.1007/s12561-011-9040-7     Document Type: Article

References (28)

1. Bang H, Robins JM (2005) Doubly robust estimation in missing data and causal inference models. Biometrics 61: 692-972.
2. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán MA (2010) When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat 6: 18.
3. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, von Esteve A, Casabona J, del Amo J, Moreno S, Meyer L, Pérez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernán MA (HIV-CAUSAL Collaboration) (2011) When to initiate combined antiretroviral therapy to reduce rates of mortality and AIDS in HIV-infected individuals in developed countries. Ann Intern Med 154(8): 509-515.
4. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351(9102): 543-549.
5. CDC (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mort Wkly Rep 41: 1-19.
6. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A (2003) Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158(7): 687-694.
7. European AIDS Clinical Society (2009) Guidelines: clinical management and treatment of HIV infected adults in Europe. http://www. europeanaidsclinicalsociety. org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults. pdf.
8. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337(11): 725-733.
9. Hernán MA, Lanoy E, Costagliola D, Robins JM (2006) Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 98: 237-242.
10. van der Laan MJ (2010a) Targeted maximum likelihood based causal inference: Part I. Int J Biostat 6(2): 2.
11. van der Laan MJ (2010b) Targeted maximum likelihood based causal inference: Part II. Int J Biostat 6(2): 3.
12. van der Laan MJ, Petersen ML (2007) Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat 3(1): 3.
13. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD (EuroSIDA study group) (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370(9585): 407-413.
14. Murphy SA, van der Laan MJ, Robins JM (2001) Marginal mean models for dynamic regimes. J Am Stat Assoc 96(456): 1410-1423.
15. NIH (2009) Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). Vol 2009.
16. Orellana L, Rotnitzky A, Robins JM (2010a) Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes. Part I: Main content. Int J Biostat 6: 7.
17. Orellana L, Rotnitzky A, Robins JM (2010b) Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes. Part II: Proofs and additional results. Int J Biostat 6: 8.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents (2009) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://www. aidsinfo. nih. gov/ContentFiles/AdultandAdolescentGL. pdf.
19. Petersen ML, Deeks SJ, van der Laan MJ (2007) Individualized treatment rules: Generating candidate clinical trials. Stat Med 26(25): 4578-4601.
20. Petersen ML, Porter KE, Gruber S, Wang Y, van der Laan MJ (2010, in print) Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res.
21. Ray M, Logan R, Sterne J, Hernández-Díaz S, Robins J, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher H, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, Garcia de Olalla P, Hernán MA (The HIV-CAUSAL Collaboration PG) (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24(1): 123-137.
22. Robins JM (1986) A new approach to causal inference in mortality studies with a sustained exposure period: application to the healthy worker survivor effect. Math Model 7: 1393-1512 [Errata (1987) in Comput Math Appl 14: 917-921. Addendum (1987) in Comput Math Appl 14: 923-945. Errata (1987) to addendum in Comput Math Appl 18: 477.].
23. Robins JM (1997) Causal inference from complex longitudinal data. In: Berkane M (ed) Latent variable modeling and applications to causality. Lecture notes in statistics, vol 120. Springer, Berlin, pp 69-117.
24. Robins JM, Hernán MA (2009) Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G (eds) Advances in longitudinal data analysis. Chapman and Hall/CRC Press, Boca Raton, pp 553-599.
25. Robins JM, Hernán MA, Siebert U (2004) Effects of multiple interventions. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL (eds) Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. World Health Organization, Geneva.
26. Taubman SL, Robins JM, Mittleman MA, Hernán MA (2009) Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol 38(6): 1599-1611.
27. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 304(3): 321-333.
28. World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. http://www. who. int/hiv/pub/arv/rapid_advice_art. pdf.